Riboxin - instructions for use, dose, side effects, contraindications

Active substance:
Inosine (Riboxin) in terms of 100% substance	- 200 mg
Excipients:
sucrose (refined sugar)	-16.3 mg
calcium stearate monohydrate	- 2.72 mg
gelatin	- 3.26 mg
potato starch	- 49.72 mg
Shell composition:
hypromellose (hydroxypropylmethylcellulose)	- 3.27 mg
polysorbate-80 (Tween 80)	- 0.95 mg
titanium dioxide	- 0.658 mg
paraffin liquid (oil vaseline)	- 1.11 mg
dye quinoline yellow E 104	- 0.012 mg

Description:Round, biconcave tablets, covered with a film membrane, from light yellow to yellow with an orange tinge. On the cross-section, two layers are visible: the outer one is yellow, the inner one is white.

Pharmacotherapeutic group:metabolic

ATX: & nbsp

C.01.E.B Other drugs for the treatment of heart disease

Pharmacodynamics:

Metabolic agent, a precursor of adenosine triphosphate; has antihypoxic, metabolic and antiarrhythmic effects. Increases the energy balance of the myocardium, improves coronary circulation, prevents the consequences of intraoperative kidney ischemia. Activates the metabolism of pyruvic acid to ensure a normal process of tissue respiration, and also promotes the activation of xanthine dehydrogenase. Stimulates the synthesis of nucleotides, enhances the activity of certain enzymes of the Krebs cycle.Penetrating into cells, increases the energy level, has a positive effect on the metabolic processes in the myocardium, increases the strength of the heart contractions and promotes more complete relaxation of the myocardium in diastole, resulting in an increase in the shock volume of blood. Reduces the aggregation of platelets.

Pharmacokinetics:

It is well absorbed in the gastrointestinal tract. Metabolised in the liver with the formation of glucuronic acid and its subsequent oxidation. In a small amount is excreted by the kidneys.

Indications:

Riboxin is prescribed for adults in complex therapy: coronary heart disease, myocardial dystrophies, myocardial infarction, cardiac rhythm disorders due to the use of cardiac glycosides.

Assign with hepatitis, cirrhosis, fatty liver disease caused by alcohol or drugs, and urocoppororphy.

Contraindications:

Hypersensitivity to the drug, gout, hyperuricemia.

Carefully:

Renal failure.

Pregnancy and lactation:

The drug should be prescribed only in cases where the benefit to the mother exceeds the potential risk to the fetus and the baby.

Dosing and Administration:

Inside before eating.

The maximum daily dose of the drug for oral administration is 0.6-2.4 g. In the first days of treatment, the daily dose is 0.6-0.8 g (0.2 g 3-4 times a day). If the drug is well tolerated, the dose is increased for 2-3 days to 1.2 g (0.4 g 3 times a day), if necessary - up to 2.4 g per day.

Duration of the course - from 4 weeks to 1,5-3 months.

With urocoppororphy, the daily dose is 0.8 g (0.2 g 4 times a day).

The drug is taken daily for 1-3 months.

Side effects:

Hyperuricemia and exacerbation of gout (with prolonged intake of high doses), allergic reactions (urticaria, skin itching, skin hyperemia).

Overdose:

Treatment is symptomatic.

Interaction:

At present, there is no clinically significant interaction of inosine with other drugs.

Effect on the ability to drive transp. cf. and fur:

The drug does not adversely affect the performance of potentially hazardous activities requiring increased concentration of attention and speed of psychomotor reactions, as well as the management of motor vehicles.

Form release / dosage:Tablets, film-coated, 200 mg.

Packaging:

For 10 tablets in a contour mesh box made of polyvinylchloride film and foil of aluminum printed lacquered or paper with a polymer coating.

For 50 tablets in cans of orange glass or in cans of polymeric.

1 jar or 5 contour mesh packages together with instructions for use are placed in a pack of cardboard.

Storage conditions:

In a dry, protected from light place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:3 years.

Do not use after the expiry date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:P N000814 / 02-2003

Date of registration:15.12.2008

The owner of the registration certificate:BIOSINTEZ, PAO BIOSINTEZ, PAO Russia

Manufacturer: & nbsp

BIOSINTEZ, PAO Russia

Representation: & nbspBIOSINTEZ JSC BIOSINTEZ JSC Russia

Information update date: & nbsp23.10.2015

Illustrated instructions

Instructions

Riboxin (Riboxin)